Skip to main content
Andrew Harris, MD, Pediatric Hematology & Oncology, New York, NY, Memorial Sloan Kettering Cancer Center

AndrewCHarrisMD

Pediatric Hematology & Oncology New York, NY

Associate Attending - Memorial Sloan Kettering Cancer Center

Overview of Dr. Harris

Dr. Andrew Harris is a pediatric hematologist/oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Case Western Reserve University School of Medicine and has been in practice 12 years. He is one of 92 doctors at Memorial Sloan Kettering Cancer Center who specialize in Pediatric Hematology & Oncology. He has more than 60 publications and over 500 citings.

Education & Training

  • University of Michigan Health System
    University of Michigan Health SystemFellowship, Pediatric Hematology/Oncology, 2008 - 2011
  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationResidency, Pediatrics, 2005 - 2008
  • Case Western Reserve University School of Medicine
    Case Western Reserve University School of MedicineClass of 2005

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • NY State Medical License
    NY State Medical License 2021 - 2024
  • UT State Medical License
    UT State Medical License 2015 - 2022
  • MI State Medical License
    MI State Medical License 2008 - 2018
  • OH State Medical License
    OH State Medical License 2005 - 2008
  • American Board of Pediatrics Pediatrics
  • American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Publications & Presentations

PubMed

Abstracts/Posters

  • Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World E...
    Andrew C. Harris, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results fro...
    Andrew C Harris, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Hospital Affiliations